At the headquarters of the European Medicines Agency in Amsterdam.
-
REMKO DE WAAL / ANP / AFP
The European Medicines Agency (EMA) ruled on Wednesday that blood clots should be added to the rare side effects of the AstraZeneca vaccine.
It also considers that the benefit / risk balance of the serum remains “positive”.
The EMA held a press conference on the potential link between the AstraZeneca coronavirus vaccine and blood clot formation.
It was to give "the conclusion of the examination of the alarm signal" launched about this vaccine in relation to "cases of thrombosis", said the European regulator, based in Amsterdam.
The EMA said on Tuesday it was still evaluating whether the AstraZeneca coronavirus vaccine is potentially linked to the formation of rare blood clots, reported in several countries.
An EMA official had previously mentioned the existence of a "link" between the AstraZeneca vaccine and the cases of thrombosis observed after its administration, in an interview with the Italian daily
Il Messaggero
published on Tuesday.
The EMA had announced on March 18 that the benefits of the AstraZeneca vaccine continued to outweigh the risks and that its use remained safe, after the suspension of injections by several countries.
The agency had explained, however, that there was a possible link to rare cases of blood clots, and that it would release updated advice at its safety committee meeting this week.
Health
The EMA "has not yet reached a conclusion" on the AstraZeneca vaccine
Society
Three new cases of thrombosis and two deaths associated with AstraZeneca in France
Covid 19
Coronavirus
Health
EU
AstraZeneca
Anti-covid vaccine